Summary
A 32 year old woman with severe aplastic anaemia required frequent transfusions and consequently developed hyperferrioxaemia (54 μMol/l) and hyperferritinaemia (1,700 ng/ml). For the treatment of transfusion siderosis she was given 18 high dose courses each comprising 35 g of desferrioxamine. Because of pre-existing thrombocytopenia (platelet count 5×109/l) the iron chelating agent was given by continuous intravenous infusion over 3 1/2 days. High dose desferrioxamine had to be abandoned because of severe bone pain. The desferrioxamine infusions achieved a negative iron balance, iron loss after each infusion being 100 to 200 mg in the urine and 400 mg in the faeces. Serum iron and ferritin concentrations fell almost to normal. This report shows that faecal iron excretion must be taken into account in assessing the balance of iron input and output during desferrioxamine treatment.
Similar content being viewed by others
References
AMA Drug Evaluations, 4th edition, p. 1447, Publishing Science Group, Littleton 1980
Arnold H, Wehinger H, Deus G, Löhr GW (1978) Kontrollierte Desferrioxamin-Therapie bei kongenitaler Anämie und Transfusionssiderose. Dtsch Med Wochenschr 103: 1240–1244
Brückner R, Hess R, Keberle H, Pericin C, Tripod I (1967) Tierexperimentelle pathologische Linsenveränderungen nach langdauernder Verabreichung hoher Dosen von Desferal. Helv Physiol Pharmacol Acta 25: 62–77
Cartei G, Barbui T, Cazzavillan M, Chisesi T, Dini E (1975) Desferrioxamine B. Reversible side effects of high daily doses. Blut 31: 11–16
Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC (1977) Treatment of iron overload in adults with continuous parenteral desferrioxamine. Am J Med 63: 958–966
Cumming RLC, Smith JA, Goldberg A (1969) Clinical and laboratory studies on the action of desferrioxamine. Brit J Haemat 17: 257–263
Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER (1983) Ocular toxicity of high-dose intravenous desferrioxamine. The Lancet 2: 181–184
Harker LA, Funk DD, Finch CA (1968) Evaluation of storage iron by chelates. Am J Med 45: 105–115
Hershko Ch (1978) Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats. Blood 51: 415–423
Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119: 758–768
Miller KG, Rosenwasser LJ, Bessette J-AM, Beer DJ, Rocklin RE (1981) Rapid desensitation for desferrioxamine anaphylactic reaction. The Lancet 2: 1059
Nienhuis AW, Delea C, Aamodt R, Bartter R, Anderson WF (1976) Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload. Birth Defects 12: 177–185
O'Brien RT (1974) Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann N Y Acad Sci 232: 221–225
Peters G, Keberle H, Schmid K, Brunner H (1966) Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat. Biochem Pharmacol 15: 93–109
Pierides AM, Myli MP (1984) Iron and aluminium osteomalacia in hemodialysis patients. N Engl J Med 310: 323
Pippard MJ, Callender ST, Finch CA (1982) Ferrioxamine excretion in iron-loaded man. Blood 60: 288–294
Pippard MJ, Johnson DK, Finch CA (1982) Hepatocyte iron kinetics in the rat explored with an iron chelator. Brit J Haematol 52: 211–224
Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG (1977) Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 297: 418–423
Propper RD, Shurin SB, Nathan DG (1976) Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294: 1421–1423
Roos JTH, Price WJ (1971) Mechanism of interference and releasing action in atomic absorption spectrometry. I. Effect of citric acid on iron. Spectrochim Acta 26 B: 279–282
Sidi Y, Shaklai M, Liban E, Pinkhas J (1981) Continuous high-dose intravenous desferrioxamine treatment for iron overload. Israel J Med Sci 17: 348–351
Wapnick AA, Lynch SR, Charlton RW, Seftel HC, Bothwell TH (1969) The effect of ascorbic acid deficiency on desferrioxamine induced urinary iron excretion. Brit J Haemat 17: 563–569
Waxman HS, Brown EB (1969) Clinical usefulness of iron chelating agents. Prog in Hematol 6: 338–373
Wissenschaftliche Tabellen Geigy: Teilband Körperflüssigkeiten, 8. Auflage, Basel, 1977
Wöhler F (1962) Die Therapie der Hämochromatose. Med Klin 57: 1370–1376
World Health Organization: Report of a WHO working group on the community control of hereditary anaemias. Geneva, 9–11 November, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Breithaupt, H., Heckers, H., Pralle, H. et al. High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis. Blut 52, 211–219 (1986). https://doi.org/10.1007/BF00321080
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00321080